Everything below concerns lyophilized peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-03-03. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | GHRH analog family |
| Residue count | 44 amino acids | Matches human GHRH(1-44) backbone |
| N-terminal group | trans-3-hexenoyl | Main structural difference from native hormone |
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility class | Freely soluble in water | Peptide character; less soluble in organic solvents |
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
According to the latest official projection, Brazil's estimated population was 214,211,951 on 1 July 2026—an increase from the figure of 203 million reported by the 2022 census. The population of Brazil, as recorded by the 2008 PNAD, was approximately 190 million (22.31 inhabitants per square kilometer or 57.8/sq mi), with a ratio of men to women of 0.95:1 and 83.75% of the population defined as urban. The population is heavily concentrated in the Southeast (89 million inhabitants) and Northeast (54.6 million inhabitants), while the two most extensive regions, the Center-West and the North, which together make up 64.12% of Brazilian territory, have a total of only 33.8 million inhabitants. The first census in Brazil was carried out in 1872 and recorded a population of 9,930,478. From 1880 to 1930, four million Europeans arrived. Brazil's population increased significantly between 1940 and 1970, because of a decline in the mortality rate, even though the birth rate underwent a slight decline. In the 1940s the annual population growth rate was 2.4%, rising to 3.0% in the 1950s and remaining at 2.9% in the 1960s, as life expectancy rose from 44 to 54 years, and to 72.6 years in 2007. It has been steadily falling since the 1960s, from 3.04% per year between 1950 and 1960 to 1.05% in 2008 and is expected to fall to a negative value of –0.29% by 2050, thus completing the demographic transition. In 2022, the illiteracy rate was roughly 7%, a significant decline from 11.48% in 2008. By comparison, in 1940, more than half the population (54%) was illiterate.
Although the core of a wooden pencil is commonly referred to as "lead", wooden pencils do not contain the chemical element lead, nor have they ever contained it; "black lead" was formerly a name of graphite, which is commonly used for pencil leads.
Stews have been made since ancient times. The world's oldest known evidence of stew was found in Japan, dating to around 5000 BC during the Jōmon period. They made seafood whose ingredients varied with the seasons. The food was cooked in large conical or rounded pots with tapered or pointy bottoms that sat well in the soil and ash of the bonfire or hearth. Amazonian tribes used the shells of turtles as vessels, boiling the entrails of the turtle and various other ingredients in them.
== Names == There has been some confusion about the biological effects of synephrine because of the similarity of this un-prefixed name to the names m-synephrine, Meta-synephrine and Neosynephrine, all of which refer to a related drug and naturally occurring amine more commonly known as phenylephrine. Although there are chemical and pharmacological similarities between synephrine and phenylephrine, they are nevertheless different substances. The confusion is compounded by the fact that synephrine has been marketed as a drug under numerous different names, including Sympatol, Sympathol, Synthenate, and oxedrine, while phenylephrine has also been called m-Sympatol. The synephrine with which this article deals is sometimes referred to as p-synephrine in order to distinguish it from its positional isomers, m-synephrine and o-synephrine. A comprehensive listing of alternative names for synephrine may be found in the ChemSpider entry (see Chembox, at right). Confusion exists over the distinctions between p- and m-synephrine. However, an examination of the references cited in support of this statement show that all the evidence for the presence of m-synephrine in C. aurantium derives from a report by Penzak and co-workers, whose Abstract states that m-synephrine was found in C.
Sources: en.wikipedia.org
=== Confusion with the Fanning friction factor === The Darcy–Weisbach friction factor fD is 4 times larger than the Fanning friction factor f, so attention must be paid to note which one of these is meant in any "friction factor" chart or equation being used. Of the two, the Darcy–Weisbach factor fD is more commonly used by civil and mechanical engineers, and the Fanning factor f by chemical engineers, but care should be taken to identify the correct factor regardless of the source of the chart or formula. Note that
Superconductivity in the cuprates is considered unconventional and is not explained by BCS theory. Possible pairing mechanisms for cuprate superconductivity continue to be the subject of considerable debate and further research. Similarities between the low-temperature antiferromagnetic state in undoped materials and the low-temperature superconducting state that emerges upon doping, primarily the dx2−y2 orbital state of the Cu2+ ions, suggest that electron-phonon coupling is less relevant in cuprates. Recent work on the Fermi surface has shown that nesting occurs at four points in the antiferromagnetic Brillouin zone where spin waves exist and that the superconducting energy gap is larger at these points. The weak isotope effects observed for most cuprates contrast with conventional superconductors that are well described by BCS theory. In 1987, Philip Anderson proposed that superexchange could act as a high-temperature superconductor pairing mechanism. In 2016, Chinese physicists found a correlation between a cuprate's critical temperature and the size of the charge transfer gap in that cuprate, providing support for the superexchange hypothesis. A 2022 study found that the varying density of actual Cooper pairs in a bismuth strontium calcium copper oxide superconductor matched with numerical predictions based on superexchange. But so far there is no consensus on the mechanism, and the search for an explanation continues. Similarities and differences in the properties of hole-doped and electron-doped cuprates:
Urine testing is the most common method of testing for ketones. Urine test strips utilize a nitroprusside reaction with acetoacetate to give a semi-quantitative measure based on color change of the strip. Although beta-hydroxybutyrate is the predominant circulating ketone, urine test strips only measure acetoacetate. Urinary ketones often correlate poorly with serum levels because of variability in excretion of ketones by the kidney, influence of hydration status, and renal function.
== Mitogen-activated protein kinase 7 == Mitogen-activated protein kinase 7 (MAPK7) is also known as extracellular signal-regulated kinase 5 (ERK5). Sometimes referred to as Big MAPK or BMK due to its large size in comparison to other MAPKs.
At the hearing, he said that he "found Judge Jackson to be smart, well-versed in the law, and extraordinarily deft and artful in her ability to speak at length without saying anything of substance on critical questions—especially the limits of judicial power and the importance of judicial restraint", adding, "I don't agree with the judge on where, based on her opinions, she draws the limits of judicial power, and I don't think she places as great an importance as I do on judicial restraint in a Madisonian system of checks and balances and separation of powers, and, for that reason, I will be voting no." On July 27, 2022, Kennedy voted against the Chips and Science Act, a bill regarding semiconductor production. He called the bill "a subsidy to Big Tech", adding, "These are extraordinary American companies that Congress just helped, but they're very profitable, and the supply of chips is growing now. My concern is the amount of money. For that amount, we could have doubled the R&D tax credit for every company in America." On August 7, 2022, Kennedy voted against the Inflation Reduction Act, calling it a "massive tax-and-spending bill". While the bill was being amended, Kennedy attempted to include an amendment he drafted with Senator Raphael Warnock to cap the price of insulin at $35 per month; the amendment did not receive the 60 votes needed to be included.
Sources: en.wikipedia.org
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.
It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.
The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.